Browse treatments

…mber and complexity of trials, teaching activities derived from investigational drug management. In 2018, an exploratory survey was conducted in Spain that des…

…’, ‘psychoanaleptics’, and ‘diuretics’. In 75% (48/64) of DRPs, clinical pharmaceutical interventions were considered by ED-physicians. Thirty-six of these DRPs were…

…ollowing recurrence during or within 12 months after completing adjuvant endocrine therapy.In the pivotal INAVO120 trial, inavolisib demonstrated a benefi…

…Background and Importance Long-acting antiretroviral therapy represents a major advance in HIV management by improving adher…

…months respectively) with higher costs, indicating dominance by DTG/3TC. FTC/TAF-based combinations showed reduced durability with mixe…

…eatment of melanoma and non-small-cell lung cancer. Since then, anti-PD-1 therapies have revolutionised cancer treatment. The hospital use of nivol…

…ated with increased morbidity, mortality, and healthcare costs. Empirical antibiotic treatment should be guided by local protocols considering risk factors fo…

…ally ill patients, often with neurological conditions requiring anticonvulsant therapy. These patients frequently require concurrent administration of…

…MI 31.5±6.9, 85.3% presented type 2 asthma. 44.12% had received biologic therapy. The main outcomes were: Pre-Treatment Post-Treatment P-value F…

….2% each), spondylodiscitis (13.5%), and osteomyelitis (10.8%). Ambulatory consolidation therapy was used in 83.8% (n=31) following inpatient stabilisation. Gra…

…Importance Standard first-line treatment for high risk DLBCL is R-CHOP/COMP or R-Pola-CHP (IPI 3-5). For patients ≥80 years or those classi…

…high risk patient subgroups by analysing the combined impact of chemotherapy delivery and clinical status.Aim and Objectives The main object…